• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    AREX Capital Expresses Disappointment in Enhabit's Strategic Review Conclusion

    5/9/24 9:15:54 AM ET
    $ADUS
    $BKD
    $EHAB
    $ELV
    Medical/Nursing Services
    Health Care
    Hospital/Nursing Management
    Health Care
    Get the next $ADUS alert in real time by email

    Believes Enhabit's Shares Do Not Reflect its Intrinsic Value or Strategic Potential

    Has Nominated Seven Highly Qualified Independent Directors

    Believes AREX Slate Would Provide Board With Sorely Needed Home Health and Hospice Expertise

    NEW YORK, May 09, 2024 (GLOBE NEWSWIRE) -- AREX Capital Management, LP ("AREX Capital Management" or "we"), together with its affiliates, the owners of approximately 4.8% of the shares of Enhabit, Inc. (NYSE:EHAB) (the "Company" or "Enhabit"), today issued the below statement expressing its disappointment in the conclusion of Enhabit's strategic review.

    "We are disappointed that Enhabit's strategic review process has concluded without a sale of the Company. We do not believe that this failure reflects Enhabit's intrinsic value or strategic potential. Rather, this failure lies with Enhabit's Board. In March, we nominated a slate of seven highly qualified candidates to stand for election at the 2024 Annual Meeting. We chose not to publicly disclose our nomination to avoid disrupting the strategic review process to the detriment of shareholders, but clearly our hope that this Board might finally deliver a positive result for its shareholders was wishful thinking.

    We believe that Enhabit's lackluster operating performance relative to peers over the past two years plainly demonstrates that the Board urgently needs the deep operational expertise in home health and hospice that the AREX Slate would bring. The AREX Slate is eager to begin the work of driving improvement at Enhabit and maximizing value for all shareholders."

    AREX SLATE BIOGRAPHIES

    Megan Ambers

    Ms. Ambers brings a deep understanding of home health and hospice labor strategies, operations, payor models, utilization, and organizational optimization to the Board.

    • Chief People Officer of Ivy Rehab Network, Inc., an industry-leading outpatient and pediatric healthcare provider offering physical, occupational, speech and ABA therapy.
    • Previously served as the Senior Vice President of Workforce Strategy, HR Innovation & Total Rewards at Amedisys, Inc. ("Amedisys"), a leading provider of healthcare in the home with a vision of becoming the premiere solution for patients across the country to age in place, from 2018 to 2022, as well as the Interim Chief Human Resources Officer of Amedisys from March 2022 to October 2022.

    James T. Corcoran

    Mr. Corcoran brings extensive knowledge of capital markets and corporate governance practices.

    • Partner at AREX Capital Management.
    • Previously a member of the board directors of Tuesday Morning Corporation (NASDAQ:TUES), an off-price retailer, from 2017 to 2020, where he served on the Audit and Nominating and Governance Committees.

    Maxine Hochhauser

    Ms. Hochhauser brings more than 30 years of experience as a healthcare executive, focused mainly on home health and home care operations, and a history of successfully navigating challenging financial, regulatory, and payor transitions.

    • Chief Executive Officer of HealthPRO Heritage, a national rehabilitation and health innovations company.
    • Previously served as President of the Home and Community Based Services Division of LHC Group, Inc., a provider of in-home healthcare services and innovations for communities around the nation, from 2019 to 2023.
    • Previously served as Chief Operating Officer of Addus HomeCare Corporation (NASDAQ:ADUS), a leading provider home care services that include personal care services that assist with activities of daily living, from 2014 to 2017.
    • Previously served as Senior Vice President of Enterprise Operations of Amedisys from 2012 to 2014, and AllianceCare, Inc., a private equity owned home healthcare company, from 2008 to 2012.

    Mark W. Ohlendorf

    Mr. Ohlendorf brings 30 years of diverse experience in senior-related healthcare, including in the home health, hospice, and senior housing markets in addition to his financial and accounting expertise.

    • Most recently served as the Managing Member of Four Peaks Advisors, LLC, a consulting practice focused on post-acute healthcare and related businesses, from 2016 to 2023.
    • Previously served as President for Brookdale Senior Living, Inc. ("Brookdale") (NYSE:BKD), the largest operator of senior living communities in the United States. During his tenure at Brookdale, he served in a variety of executive leadership roles for Brookdale and one of its predecessor companies from 1997 to 2016, including service as Brookdale's Chief Financial Officer from 2006 to 2015.
    • Previously served as Vice President and CFO for VITAS Healthcare Corporation, the nation's largest hospice and palliative care provider, from 1990 to 1997.

    Anna-Gene O'Neal

    Ms. O'Neal brings 35 years of healthcare experience, including leadership positions in home health and hospice operations, and a demonstrated ability to grow revenue and improve the quality of patient care.

    • Senior Vice President of Home Health, Hospice, and Palliative Care at HarmonyCares, a Michigan-based provider of comprehensive home-based healthcare services.
    • Previously served as the President of Brookdale's Health Care Services division, where she was responsible for home health, hospice, and outpatient therapy, from 2019 to 2021. She subsequently served as President, Hospice Service Line for HCA Healthcare, Inc. (NYSE:HCA) ("HCA") from 2021 to 2022, following HCA's acquisition of a majority stake in the business.
    • Previously served as President and CEO of Alive Hospice, a Tennessee-based non-profit hospice provider consistently ranked among the best in the nation, from 2012 to 2019.

    Dr. Gregory S. Sheff

    Dr. Sheff brings extensive knowledge of home health operations and insight into large payors along with more than 20 years of healthcare experience, both as a practicing physician and executive, with a particular focus on home- and value-based care.

    • Previously served as Interim President, Home Solutions at Humana, Inc. (NYSE:HUM) from 2021 to 2022, as well as Chief Medical Officer, Home Solutions, from 2020 to 2022. He oversaw Humana's home-focused delivery segment, where he was responsible for operations, partnerships, and integration of multiple home-based care assets, from primary care to hospital at home to Medicare-certified home health.
    • Previously served as Executive Vice President and Chief Medical Officer of AccentCare, one of the nation's leaders in home-based healthcare services, from 2015 to 2019.

    Juan Vallarino

    Mr. Vallarino brings more than 40 years of experience in the healthcare industry, coupled with his extensive knowledge of multifaceted home health and post-acute experience along with a deep understanding of managed care payor negotiations.

    • President and Chief Executive Officer of MyLaurel Health, a leader in providing high-acuity, high-complexity care in patients' homes.
    • Previously served as Chief Executive Officer of myNEXUS, a leading provider of comprehensive home-based nursing management to health insurers, from 2019 until its successful sale in 2021 to Anthem Inc. (now known as Elevance Health, Inc. (NYSE: ELV)). He also served myNEXUS as a Vice Chairman and in a strategic advisor role from 2018 to 2019.
    • Previously spent over two decades with HCA and its predecessor companies from 1993 to 2016. Most recently he served as Senior Vice President of Employer and Payer Engagement with responsibility for over $30 billion in net revenue.

    About AREX

    AREX Capital Management, LP is a value-oriented investment firm based in New York City. AREX takes a long-term, opportunistic approach to investing and focuses primarily on publicly traded companies with significant, unrealized potential.

    Media Contact

    Valerie Toomey, Chief Operating Officer

    AREX Capital Management, LP

    (646) 679-4000

    [email protected]

    CERTAIN INFORMATION CONCERNING THE PARTICIPANTS

    AREX Capital Master Fund, LP, an exempted limited partnership organized under the laws of the Cayman Islands ("AREX Capital Master"), together with the other participants named herein, intends to file a preliminary proxy statement and accompanying WHITE universal proxy card with the Securities and Exchange Commission ("SEC") to be used to solicit votes for the election of its slate of highly qualified director nominees at the 2024 annual meeting of stockholders of Enhabit, Inc., a Delaware corporation (the "Company").

    AREX CAPITAL MASTER STRONGLY ADVISES ALL STOCKHOLDERS OF THE COMPANY TO READ THE PROXY STATEMENT AND OTHER PROXY MATERIALS AS THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. SUCH PROXY MATERIALS WILL BE AVAILABLE AT NO CHARGE ON THE SEC'S WEB SITE AT HTTP://WWW.SEC.GOV. IN ADDITION, THE PARTICIPANTS IN THIS PROXY SOLICITATION WILL PROVIDE COPIES OF THE PROXY STATEMENT WITHOUT CHARGE, WHEN AVAILABLE, UPON REQUEST. REQUESTS FOR COPIES SHOULD BE DIRECTED TO THE PARTICIPANTS' PROXY SOLICITOR.

    The participants in the proxy solicitation are anticipated to be AREX Capital Master, AREX Capital Partners, LP, a Delaware limited partnership ("AREX Capital Partners"), AREX Capital, Ltd., a Cayman Islands exempted company ("AREX Limited"), AREX Capital GP, LLC, a Delaware limited partnership ("AREX Capital GP"), AREX Capital Management, LP, a Delaware limited partnership ("AREX Capital Management"), AREX Capital Management GP, LLC, a Delaware limited liability company ("AREX Capital Management GP"), Andrew Rechtschaffen, Megan Ambers, James T. Corcoran, Maxine Hochhauser, Mark W. Ohlendorf, Anna-Gene O'Neal, Dr. Gregory S. Sheff, and Juan Vallarino.

    As of the date hereof, AREX Capital Master directly beneficially owns 549,277 shares of common stock, par value $0.01 per share, of the Company (the "Common Stock") and has economic exposure to an aggregate of 54,782 notional shares of Common Stock pursuant to certain cash-settled total return swap agreements. Each of AREX Capital Partners and AREX Limited, as feeder funds of AREX Capital Master, may be deemed to beneficially own the 549,277 shares of Common Stock owned by AREX Capital Master. AREX Capital GP, as the general partner of AREX Capital Master, may be deemed to beneficially own the 549,277 shares of Common Stock owned by AREX Capital Master. AREX Capital Management, as the investment advisor of each of AREX Capital Master and certain accounts separately managed by AREX Capital Management (the "AREX Managed Accounts"), may be deemed to beneficially own the 2,425,809 shares of Common Stock owned in the aggregate by AREX Capital Master and held in the AREX Managed Accounts. AREX Capital Management GP, as the general partner of AREX Capital Management, may be deemed to beneficially own the 2,425,809 shares of Common Stock owned in the aggregate by AREX Capital Master and held in the AREX Managed Accounts. Mr. Rechtschaffen, as the Managing Member of each of AREX Capital GP and AREX Capital Management GP, may be deemed to beneficially own the 2,425,809 shares of Common Stock owned in the aggregate by AREX Capital Master and held in the AREX Managed Accounts. As of the date hereof, none of Mses. Ambers, Hochhauser nor O'Neal, nor Messrs. Corcoran, Ohlendorf nor Vallarino, nor Dr. Sheff own any shares of Common Stock. 



    Primary Logo

    Get the next $ADUS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ADUS
    $BKD
    $EHAB
    $ELV

    CompanyDatePrice TargetRatingAnalyst
    Enhabit Inc.
    $EHAB
    3/6/2026$13.80Buy → Hold
    TD Cowen
    Humana Inc.
    $HUM
    2/12/2026$189.00Outperform → Sector Perform
    RBC Capital Mkts
    Elevance Health Inc.
    $ELV
    2/3/2026$358.00Outperform → Sector Perform
    RBC Capital Mkts
    Humana Inc.
    $HUM
    2/2/2026$174.00Equal-Weight → Underweight
    Morgan Stanley
    Enhabit Inc.
    $EHAB
    1/22/2026$14.00Perform → Outperform
    Oppenheimer
    Enhabit Inc.
    $EHAB
    1/13/2026$12.00Hold → Buy
    TD Cowen
    Enhabit Inc.
    $EHAB
    1/8/2026$12.00Neutral → Buy
    UBS
    Elevance Health Inc.
    $ELV
    1/8/2026$425.00Peer Perform → Outperform
    Wolfe Research
    More analyst ratings

    $ADUS
    $BKD
    $EHAB
    $ELV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Enhabit Inc. downgraded by TD Cowen with a new price target

    TD Cowen downgraded Enhabit Inc. from Buy to Hold and set a new price target of $13.80

    3/6/26 8:25:46 AM ET
    $EHAB
    Medical/Nursing Services
    Health Care

    Humana downgraded by RBC Capital Mkts with a new price target

    RBC Capital Mkts downgraded Humana from Outperform to Sector Perform and set a new price target of $189.00

    2/12/26 8:16:45 AM ET
    $HUM
    Medical Specialities
    Health Care

    Elevance Health downgraded by RBC Capital Mkts with a new price target

    RBC Capital Mkts downgraded Elevance Health from Outperform to Sector Perform and set a new price target of $358.00

    2/3/26 6:49:01 AM ET
    $ELV
    Medical Specialities
    Health Care

    $ADUS
    $BKD
    $EHAB
    $ELV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Accounting Officer Mcquiddy Collin sold $19,095 worth of shares (1,403 units at $13.61), decreasing direct ownership by 26% to 3,991 units (SEC Form 4)

    4 - Enhabit, Inc. (0001803737) (Issuer)

    3/11/26 9:18:15 PM ET
    $EHAB
    Medical/Nursing Services
    Health Care

    EVP of Home Health Operations Jolley Julie Diane sold $76,137 worth of shares (5,586 units at $13.63), decreasing direct ownership by 4% to 137,130 units (SEC Form 4)

    4 - Enhabit, Inc. (0001803737) (Issuer)

    3/11/26 9:16:57 PM ET
    $EHAB
    Medical/Nursing Services
    Health Care

    Amendment: Chief Human Resources Officer Marion Tanya Renee was granted 10,287 shares, increasing direct ownership by 11% to 103,339 units (SEC Form 4)

    4/A - Enhabit, Inc. (0001803737) (Issuer)

    3/11/26 9:16:11 PM ET
    $EHAB
    Medical/Nursing Services
    Health Care

    $ADUS
    $BKD
    $EHAB
    $ELV
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Collis Steven H bought $869,520 worth of shares (3,000 units at $289.84), increasing direct ownership by 469% to 3,639 units (SEC Form 4)

    4 - Elevance Health, Inc. (0001156039) (Issuer)

    3/6/26 8:03:27 AM ET
    $ELV
    Medical Specialities
    Health Care

    President, CenterWell Shetty Sanjay K bought $150,016 worth of Humana Common (810 units at $185.21), increasing direct ownership by 7% to 11,657 units (SEC Form 4)

    4 - HUMANA INC (0000049071) (Issuer)

    2/25/26 11:48:38 AM ET
    $HUM
    Medical Specialities
    Health Care

    Director Devore Susan D. bought $374,580 worth of shares (1,200 units at $312.15), increasing direct ownership by 52% to 3,502 units (SEC Form 4)

    4 - Elevance Health, Inc. (0001156039) (Issuer)

    8/21/25 4:20:38 PM ET
    $ELV
    Medical Specialities
    Health Care

    $ADUS
    $BKD
    $EHAB
    $ELV
    SEC Filings

    View All

    SEC Form DEFA14A filed by HCA Healthcare Inc.

    DEFA14A - HCA Healthcare, Inc. (0000860730) (Filer)

    3/13/26 4:12:14 PM ET
    $HCA
    Hospital/Nursing Management
    Health Care

    SEC Form DEF 14A filed by HCA Healthcare Inc.

    DEF 14A - HCA Healthcare, Inc. (0000860730) (Filer)

    3/13/26 4:10:44 PM ET
    $HCA
    Hospital/Nursing Management
    Health Care

    Amendment: SEC Form 10-K/A filed by Addus HomeCare Corporation

    10-K/A - Addus HomeCare Corp (0001468328) (Filer)

    3/12/26 4:31:19 PM ET
    $ADUS
    Medical/Nursing Services
    Health Care

    $ADUS
    $BKD
    $EHAB
    $ELV
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Continuous Glucose Monitoring on the Rise Among Medicare Advantage Members with Type 2 Diabetes

    Study by Humana Healthcare Research and Yale School of Medicine researcher reveals significant increase in CGM usage, particularly among older adults with chronic health conditions. A new study published in the current issue of the Journal of Managed Care & Specialty Pharmacy (JMCP)—conducted by a Humana Healthcare Research team and Dr. Joseph S. Ross of the Yale School of Medicine—reveals a notable increase in the use of continuous glucose monitors (CGMs) among Medicare Advantage members with type 2 diabetes from 2021 to 2023. The study also compared the demographic and clinical characteristics of members with type 2 diabetes who used CGMs with those who did not in 2023, finding that t

    3/12/26 9:30:00 AM ET
    $HUM
    Medical Specialities
    Health Care

    92 HCA Healthcare Hospitals Earn Healthgrades Patient Safety Excellence Award

    HCA Healthcare, Inc. (NYSE:HCA), one of the nation's leading healthcare providers, today announced that 92 of its hospitals achieved the 2026 Patient Safety Excellence Award from Healthgrades for their commitment to safe, patient-centered care. This recognition is given to the top 10% of hospitals nationwide for patient safety. "We are honored to be recognized, but even more proud of the work behind it," said Dr. Randy Fagin, senior vice president and chief quality officer of HCA Healthcare. "Learning from every patient and continuously strengthening the systems that help our caregivers deliver safe care, every day, is our commitment to earning and keeping the trust patients place in us."

    3/10/26 8:30:00 AM ET
    $HCA
    Hospital/Nursing Management
    Health Care

    Humana Completes Aggregate $1.0 Billion Fixed-to-Fixed Rate Junior Subordinated Notes Offering

    Humana Inc. (the "company") (NYSE:HUM) announced today the completion of its public offering of $1.0 billion in aggregate principal amount of fixed-to-fixed rate junior subordinated notes due 2056, at 6.625 percent of the principal amount (the "Junior Subordinated Notes Offering"). The company expects net proceeds from the Junior Subordinated Notes Offering will be approximately $986 million after deducting underwriters' discounts and estimated offering expenses. The company intends to use the net proceeds from the Junior Subordinated Notes Offering for general corporate purposes, which may include the repayment of existing indebtedness, including borrowings under its commercial paper pro

    3/9/26 5:00:00 PM ET
    $HUM
    Medical Specialities
    Health Care

    $ADUS
    $BKD
    $EHAB
    $ELV
    Leadership Updates

    Live Leadership Updates

    View All

    Elevance Health Announces Management Changes; CFO Mark Kaye to Expand Responsibilities to Include Carelon and Felicia Norwood to Lead Consolidated Health Benefits Organization

    Elevance Health, Inc. (NYSE:ELV) today announced management changes designed to simplify decision-making and strengthen execution across Carelon and Health Benefits. As part of these changes, Mark Kaye, Executive Vice President and Chief Financial Officer, will expand his responsibilities to include oversight of Carelon, the Company's healthcare services operations including pharmacy services, behavioral health, value-based care, and care delivery capabilities. Carelon plays a critical role in advancing the Company's strategy to lower the cost of care. Carelon's operating priorities and client commitments remain unchanged. Felicia Norwood, Executive Vice President and Chief Health Benef

    2/26/26 3:02:00 PM ET
    $ELV
    Medical Specialities
    Health Care

    Humana Announces Insurance Leadership Transition

    George Renaudin to Retire as Insurance Segment President by Q3 2026 Aaron Martin to Join as President of Medicare Advantage and Insurance Segment President Successor John Barger to Succeed Martin as President of Medicare Advantage Humana Inc. (NYSE:HUM) today announced that George Renaudin, Insurance Segment President and member of Humana's Enterprise Leadership Team, will retire by Q3 2026 following a successful 29-year career at the company. During this period, Renaudin played a pivotal role in establishing and growing Humana's Medicare Advantage and Medicaid programs, helping to build them into high-performing businesses and assembling a strong insurance leadership team. "George has co

    12/16/25 8:05:00 AM ET
    $HUM
    Medical Specialities
    Health Care

    Elevance Health Board Welcomes Amy Schulman as New Director, Reflecting Ongoing Commitment to Governance Excellence

    The board of directors of Elevance Health (NYSE:ELV) today announced the appointment of Amy Schulman, a recognized healthcare executive, investor, and governance leader, as an independent director, effective January 12, 2026. Schulman will serve on the Audit and Finance Committees, contributing deep expertise in healthcare innovation, regulatory strategy, and value creation across complex, global enterprises. This appointment reflects Elevance Health's ongoing board refreshment strategy to ensure diverse, independent, and future-focused leadership that aligns with the company's long-term strategy and stakeholders' priorities. "Amy's record of driving innovation, disciplined investment, an

    12/10/25 4:30:00 PM ET
    $ELV
    Medical Specialities
    Health Care

    $ADUS
    $BKD
    $EHAB
    $ELV
    Financials

    Live finance-specific insights

    View All

    Enhabit Reports Fourth Quarter 2025 Financial Results

    Enhabit, Inc. (NYSE:EHAB), a leading home health and hospice care provider, today reported its results of operations for the fourth quarter ended Dec. 31, 2025. "Our fourth quarter 2025 results capped a pivotal year for Enhabit, delivering an emerging growth story with year over year increases in patient census, revenue and Adjusted EBITDA," said Barb Jacobsmeyer, CEO and president of Enhabit. "The consistent execution of our strategy throughout the year materially improved free cash flow, enabling us to further strengthen our balance sheet, positioning us well to accelerate growth and investment in 2026." QUARTERLY PERFORMANCE - CONSOLIDATED Net service revenue of $270.4 million

    3/4/26 4:10:00 PM ET
    $EHAB
    Medical/Nursing Services
    Health Care

    Addus HomeCare Announces Fourth Quarter and Year End 2025 Financial Results

    Addus HomeCare Corporation (NASDAQ:ADUS), a provider of home care services, today announced its financial results for the fourth quarter and year ended December 31, 2025. Fourth Quarter 2025 Highlights: Net Service Revenues Increase 25.6% to $373.1 Million Net Income of $29.8 Million, or $1.61 per Diluted Share Adjusted Net Income per Diluted Share Increases 28.3% year-over-year to $1.77 Adjusted EBITDA Increases 33.3% year-over-year to $50.3 Million Cash Flow from Operations of $18.8 Million Overview Net service revenues were $373.1 million for the fourth quarter of 2025, a 25.6% increase compared with $297.1 million for the fourth quarter of 2024. Net income was $29.

    2/23/26 4:05:00 PM ET
    $ADUS
    Medical/Nursing Services
    Health Care

    Enhabit to be Acquired by Kinderhook Industries

    Enhabit, Inc. Stockholders to Receive $13.80 per Share in Cash Enhabit, Inc. (NYSE:EHAB), a leading national home health and hospice provider, today announced it has entered into a definitive agreement to be acquired by Kinderhook Industries, LLC ("Kinderhook"), a middle market private equity firm, in an all-cash transaction for a total enterprise value of approximately $1.1 billion. Under the terms of the agreement, Enhabit stockholders will receive $13.80 per share in cash, which represents a premium of approximately 24.4% to the Company's closing stock price on February 20, 2026, the last full trading day prior to the announcement of the transaction, and a 33.8% premium to the Compan

    2/23/26 8:00:00 AM ET
    $EHAB
    Medical/Nursing Services
    Health Care

    $ADUS
    $BKD
    $EHAB
    $ELV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Enhabit Inc.

    SC 13G - Enhabit, Inc. (0001803737) (Subject)

    11/14/24 9:12:39 PM ET
    $EHAB
    Medical/Nursing Services
    Health Care

    Amendment: SEC Form SC 13G/A filed by Brookdale Senior Living Inc.

    SC 13G/A - Brookdale Senior Living Inc. (0001332349) (Subject)

    11/14/24 4:43:24 PM ET
    $BKD
    Hospital/Nursing Management
    Health Care

    Amendment: SEC Form SC 13G/A filed by Brookdale Senior Living Inc.

    SC 13G/A - Brookdale Senior Living Inc. (0001332349) (Subject)

    11/14/24 4:17:59 PM ET
    $BKD
    Hospital/Nursing Management
    Health Care